Maa: Kanada
Kieli: englanti
Lähde: Health Canada
MILRINONE (MILRINONE LACTATE)
TEVA CANADA LIMITED
C01CE02
MILRINONE
1MG
SOLUTION
MILRINONE (MILRINONE LACTATE) 1MG
INTRAVENOUS
10/20/50ML
Prescription
CARDIOTONIC AGENTS
Active ingredient group (AIG) number: 0131285001; AHFS:
CANCELLED POST MARKET
2015-07-22
PRODUCT MONOGRAPH MILRINONE INJECTION (milrinone lactate injection) 1 mg/mL milrinone as lactate 10 mL, 20 mL and 50 mL vials Inotrope/Vasodilator Teva Canada Limited Date of Preparation: 30 Novopharm Court May 28, 2014 Toronto, Ontario M1B 2K9 CONTROL NO: 174105 -2- PRODUCT MONOGRAPH MILRINONE INJECTION (milrinone lactate injection) 1 mg/mL milrinone as lactate 10 mL, 20 mL and 50 mL vials THERAPEUTIC CLASSIFICATION Inotrope/Vasodilator ACTION AND CLINICAL PHARMACOLOGY Milrinone Injection (milrinone lactate injection) is a positive inotrope and vasodilator with little chronotropic activity, different in structure and mode of action from either the digitalis glycosides or catecholamines. Milrinone, at relevant inotropic and vasorelaxant concentrations, is a selective inhibitor of peak III cAMP phosphodiesterase isozyme in cardiac and vascular muscle. This inhibitory action is consistent with cAMP mediated decreases in intracellular ionized calcium and contractile force in cardiac muscle, as well as with cAMP dependent contractile protein phosphorylation and relaxation in vascular muscle. Additional experimental evidence also indicates that it is not a -2- beta-adrenergic agonist, nor does it inhibit sodium-potassium adenosine triphosphatase activity as do the digitalis glycosides. Clinical studies in patients with congestive heart failure have shown that milrinone produces dose and plasma level-related increase in left ventricular dP/dt, increase in forearm blood flow indicating a direct arterial vasodilator activity of the drug, and improves diastolic function as evidenced by improvement in left ventricular diastolic relaxation. Studies in normal subjects have shown that milrinone produces increases in the slope of the left ventricular pressure dimension relationship, indicating a direct inotropic effect of the drug. Both the inotropic and vasodilatory effects have been observed over the therapeutic range of milrinone plasma concentrations of 100 to300 ng/mL. PHARMACOKINETICS Following intravenous loading inject Lue koko asiakirja